Back

Bivalency of natalizumab promotes inhibition of dynamic VLA-4 adhesion beyond affinity gain

Valignat, M.-P.; Biarnes, M.; Touchard, D.; Ricco, A.; Chames, P.; Theodoly, O.; Robert, P.

2025-07-19 immunology
10.1101/2025.07.16.665053 bioRxiv
Show abstract

Natalizumab, a monoclonal IgG4 antibody used in the treatment of multiple sclerosis (MS), inhibits VLA-4 binding to VCAM-1, thereby reducing leukocyte recruitment to inflamed tissues. The intricate mechanisms underlying these effects remain unclear, particularly concerning the heavy-chain shuffling of IgG4. We conducted an in vitro study to quantify the impact of bivalent IgG and monovalent Fab forms of natalizumab on the capture and migration of human primary memory T lymphocytes under shear stress, using VCAM-1 and SDF-1-coated surfaces. IgG natalizumab at concentrations near its cell surface EC50 showed significant of capture and resistance of adherent cells to shear stress, whereas significantly higher doses of Fab natalizumab, up to 100-fold greater than its cell surface EC50, were needed to achieve similar effects. These findings highlight that receptor occupancy alone may not adequately predict the functional outcomes of inhibitor antibodies. For optimal therapeutic effect, inhibition of cell-surface adhesion may require specific kinetic and geometric binding properties of antibodies.

Published in Integrative Biology (predicted rank #20) · training set

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.